---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-179950"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2024-07-17T23:59:59+00:00"
generated_at: "2026-05-31T20:14:21.664742+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# 4D-150 Phase 2 interim data shows 89% injection rate reduction, 77% injection-free at 24 weeks in wet AMD

## Summary
- Planned Phase 3 dose (3E10 vg/eye): 89% reduction in mean annualized injection rate; 77% injection-free at 24 weeks.
- No 4D-150-related SAEs, no hypotony, retinal vasculitis, or choroidal effusions observed in any patient across trials (n=139).
- BCVA improved by +4.2 letters from baseline at 3E10 dose; injection-free patients saw +4.7 letters; dose response favored higher dose.
- Phase 1 patients (n=3) treated at 3E10 remained injection-free through ~2-2.5 years; BCVA and CST stable.
- Expects to announce Phase 3 trial design in Sep 2024, initiate in Q1 2025; 52-week data and DME data due in H2 2024/early 2025.

## SEC filing metadata
- accession: 0001193125-24-179950
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2024-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312524179950/0001193125-24-179950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312524179950/d873208d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-179950
- JSON: https://secwatch.observer/filing/0001193125-24-179950.json
- Plain text: https://secwatch.observer/filing/0001193125-24-179950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.